The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by45ca kinetics in the intact rat
- 1 March 1996
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 6 (2) , 166-170
- https://doi.org/10.1007/bf01623942
Abstract
The new bisphosphonate ibandronate was given at various doses and regimens to normal growing rats, and its effect on calcium metabolism investigated by means of45Ca kinetics. The bisphosphonate began to inhibit bone resorption at a dose of 0.1 µg P/kg, given daily. At higher doses intestinal calcium absorption, calciuria and calcium balance were also increased, calcemia being decreased. There was no difference in effect when the same amount of compound was given either daily for 10 days or all at once. Furthermore, the effect of a high dose of 100 µg P/kg was present 1 month after a single administration, whereas a dose 10 times lower was no longer effective. These results suggest that ibandronate may be effective in humans for decreasing bone resorption and increasing calcium balance in osteoporosis, when given either daily or discontinuously.Keywords
This publication has 15 references indexed in Scilit:
- Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodelingThe American Journal of Medicine, 1995
- Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopauseOsteoporosis International, 1994
- A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogsJournal of Bone and Mineral Research, 1993
- Effects of one-year cyclical treatment with clodronate on postmenopausal bone lossBone, 1993
- Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronateBritish Journal of Cancer, 1993
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATEThe Lancet, 1989
- Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APDBone and Mineral, 1989
- Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivoScience, 1969